A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children

M. Duchowny, J. M. Pellock, W. D. Graf, C. Billard, J. Gilman, E. Casale, G. Womble, M. Risner, P. Manasco

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Objective: To compare the safety and efficacy of add-on lamotrigine and placebo in the treatment of children and adolescents with partial seizures. Background: Add-on and monotherapy lamotrigine is safe and effective in adults with partial seizures, and reports of preliminary uncontrolled trials suggest similar benefits in children. Methods: We studied 201 children with diagnoses of partial seizures of any subtype currently receiving stable conventional regimens of antiepileptic therapy at 40 study sites in the United States and France. After a baseline observation period (to confirm that more than four seizures occurred in each of two consecutive 4-week periods), patients were randomized to add-on lamotrigine or placebo therapy. A 6-week dose-escalation period was followed by a 12-week maintenance period. Results: Compared with placebo, lamotrigine significantly reduced the frequency of all partial seizures and the frequency of secondarily generalized partial seizures in these treatment-resistant patients. The most commonly reported adverse events in the lamotrigine-treated patients were vomiting, somnolence, and infection; the frequency of these and other adverse events was similar to that in the placebo-treated group, with the exception of ataxia, dizziness, tremor, and nausea, which were more frequent in the lamotrigine-treated group. The frequency of withdrawals for adverse events was similar between groups. Two patients were hospitalized for skin rash, which resolved after discontinuation of lamotrigine therapy. Conclusions: Lamotrigine was effective for the adjunctive treatment of partial seizures in children and demonstrated an acceptable safety profile.

Original languageEnglish
Pages (from-to)1724-1731
Number of pages8
JournalNeurology
Volume53
Issue number8
StatePublished - Nov 10 1999

Fingerprint

Seizures
Placebos
Therapeutics
Safety
lamotrigine
Dizziness
Tremor
Ataxia
Exanthema
Anticonvulsants
Nausea
France
Vomiting
Maintenance
Observation
Infection

Keywords

  • Epilepsy
  • Lamotrigine
  • Partial seizures
  • Pediatric

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Duchowny, M., Pellock, J. M., Graf, W. D., Billard, C., Gilman, J., Casale, E., ... Manasco, P. (1999). A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology, 53(8), 1724-1731.

A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. / Duchowny, M.; Pellock, J. M.; Graf, W. D.; Billard, C.; Gilman, J.; Casale, E.; Womble, G.; Risner, M.; Manasco, P.

In: Neurology, Vol. 53, No. 8, 10.11.1999, p. 1724-1731.

Research output: Contribution to journalArticle

Duchowny, M, Pellock, JM, Graf, WD, Billard, C, Gilman, J, Casale, E, Womble, G, Risner, M & Manasco, P 1999, 'A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children', Neurology, vol. 53, no. 8, pp. 1724-1731.
Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology. 1999 Nov 10;53(8):1724-1731.
Duchowny, M. ; Pellock, J. M. ; Graf, W. D. ; Billard, C. ; Gilman, J. ; Casale, E. ; Womble, G. ; Risner, M. ; Manasco, P. / A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. In: Neurology. 1999 ; Vol. 53, No. 8. pp. 1724-1731.
@article{689e13695b474cecb279839353fd4854,
title = "A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children",
abstract = "Objective: To compare the safety and efficacy of add-on lamotrigine and placebo in the treatment of children and adolescents with partial seizures. Background: Add-on and monotherapy lamotrigine is safe and effective in adults with partial seizures, and reports of preliminary uncontrolled trials suggest similar benefits in children. Methods: We studied 201 children with diagnoses of partial seizures of any subtype currently receiving stable conventional regimens of antiepileptic therapy at 40 study sites in the United States and France. After a baseline observation period (to confirm that more than four seizures occurred in each of two consecutive 4-week periods), patients were randomized to add-on lamotrigine or placebo therapy. A 6-week dose-escalation period was followed by a 12-week maintenance period. Results: Compared with placebo, lamotrigine significantly reduced the frequency of all partial seizures and the frequency of secondarily generalized partial seizures in these treatment-resistant patients. The most commonly reported adverse events in the lamotrigine-treated patients were vomiting, somnolence, and infection; the frequency of these and other adverse events was similar to that in the placebo-treated group, with the exception of ataxia, dizziness, tremor, and nausea, which were more frequent in the lamotrigine-treated group. The frequency of withdrawals for adverse events was similar between groups. Two patients were hospitalized for skin rash, which resolved after discontinuation of lamotrigine therapy. Conclusions: Lamotrigine was effective for the adjunctive treatment of partial seizures in children and demonstrated an acceptable safety profile.",
keywords = "Epilepsy, Lamotrigine, Partial seizures, Pediatric",
author = "M. Duchowny and Pellock, {J. M.} and Graf, {W. D.} and C. Billard and J. Gilman and E. Casale and G. Womble and M. Risner and P. Manasco",
year = "1999",
month = "11",
day = "10",
language = "English",
volume = "53",
pages = "1724--1731",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children

AU - Duchowny, M.

AU - Pellock, J. M.

AU - Graf, W. D.

AU - Billard, C.

AU - Gilman, J.

AU - Casale, E.

AU - Womble, G.

AU - Risner, M.

AU - Manasco, P.

PY - 1999/11/10

Y1 - 1999/11/10

N2 - Objective: To compare the safety and efficacy of add-on lamotrigine and placebo in the treatment of children and adolescents with partial seizures. Background: Add-on and monotherapy lamotrigine is safe and effective in adults with partial seizures, and reports of preliminary uncontrolled trials suggest similar benefits in children. Methods: We studied 201 children with diagnoses of partial seizures of any subtype currently receiving stable conventional regimens of antiepileptic therapy at 40 study sites in the United States and France. After a baseline observation period (to confirm that more than four seizures occurred in each of two consecutive 4-week periods), patients were randomized to add-on lamotrigine or placebo therapy. A 6-week dose-escalation period was followed by a 12-week maintenance period. Results: Compared with placebo, lamotrigine significantly reduced the frequency of all partial seizures and the frequency of secondarily generalized partial seizures in these treatment-resistant patients. The most commonly reported adverse events in the lamotrigine-treated patients were vomiting, somnolence, and infection; the frequency of these and other adverse events was similar to that in the placebo-treated group, with the exception of ataxia, dizziness, tremor, and nausea, which were more frequent in the lamotrigine-treated group. The frequency of withdrawals for adverse events was similar between groups. Two patients were hospitalized for skin rash, which resolved after discontinuation of lamotrigine therapy. Conclusions: Lamotrigine was effective for the adjunctive treatment of partial seizures in children and demonstrated an acceptable safety profile.

AB - Objective: To compare the safety and efficacy of add-on lamotrigine and placebo in the treatment of children and adolescents with partial seizures. Background: Add-on and monotherapy lamotrigine is safe and effective in adults with partial seizures, and reports of preliminary uncontrolled trials suggest similar benefits in children. Methods: We studied 201 children with diagnoses of partial seizures of any subtype currently receiving stable conventional regimens of antiepileptic therapy at 40 study sites in the United States and France. After a baseline observation period (to confirm that more than four seizures occurred in each of two consecutive 4-week periods), patients were randomized to add-on lamotrigine or placebo therapy. A 6-week dose-escalation period was followed by a 12-week maintenance period. Results: Compared with placebo, lamotrigine significantly reduced the frequency of all partial seizures and the frequency of secondarily generalized partial seizures in these treatment-resistant patients. The most commonly reported adverse events in the lamotrigine-treated patients were vomiting, somnolence, and infection; the frequency of these and other adverse events was similar to that in the placebo-treated group, with the exception of ataxia, dizziness, tremor, and nausea, which were more frequent in the lamotrigine-treated group. The frequency of withdrawals for adverse events was similar between groups. Two patients were hospitalized for skin rash, which resolved after discontinuation of lamotrigine therapy. Conclusions: Lamotrigine was effective for the adjunctive treatment of partial seizures in children and demonstrated an acceptable safety profile.

KW - Epilepsy

KW - Lamotrigine

KW - Partial seizures

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=0033544351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033544351&partnerID=8YFLogxK

M3 - Article

C2 - 10563619

AN - SCOPUS:0033544351

VL - 53

SP - 1724

EP - 1731

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -